BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20152524)

  • 1. Novel targeted therapies for prostate cancer.
    Macfarlane RJ; Chi KN
    Urol Clin North Am; 2010 Feb; 37(1):105-19, Table of Contents. PubMed ID: 20152524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting continued androgen receptor signaling in prostate cancer.
    Massard C; Fizazi K
    Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate for castration resistant prostate cancer.
    Shah S; Ryan C
    Expert Opin Investig Drugs; 2010 Apr; 19(4):563-70. PubMed ID: 20225998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of fibroblast growth factors and their receptors in prostate cancer.
    Kwabi-Addo B; Ozen M; Ittmann M
    Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging treatment options for patients with castration-resistant prostate cancer.
    George D; Moul JW
    Prostate; 2012 Feb; 72(3):338-49. PubMed ID: 21748753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targeted pro-apoptotic agents for the treatment of prostate cancer.
    Huang X; Zhang X; Farahvash B; Olumi AF
    J Urol; 2007 Nov; 178(5):1846-54. PubMed ID: 17868738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-Like Growth Factor (IGF) family and prostate cancer.
    Gennigens C; Menetrier-Caux C; Droz JP
    Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial androgen receptor targeted therapy for prostate cancer.
    Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
    Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.
    Chi KN; Bjartell A; Dearnaley D; Saad F; Schröder FH; Sternberg C; Tombal B; Visakorpi T
    Eur Urol; 2009 Oct; 56(4):594-605. PubMed ID: 19560857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammalian target of rapamycin: a new target in prostate cancer.
    Rai JS; Henley MJ; Ratan HL
    Urol Oncol; 2010; 28(2):134-8. PubMed ID: 19523861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the apoptosis pathway in prostate cancer.
    Zielinski RR; Eigl BJ; Chi KN
    Cancer J; 2013; 19(1):79-89. PubMed ID: 23337761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein.
    Dorai T; Gehani N; Katz A
    Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
    McCarty MF
    Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National cooperative group trials.
    Dipaola RS; Thompson IM
    Urology; 2005 May; 65(5 Suppl):23-9; discussion 29. PubMed ID: 15885277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel drugs targeting the androgen receptor pathway in prostate cancer.
    Mateo J; Smith A; Ong M; de Bono JS
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.